• FDA medical reviewers gave a thumbs down to Debiopharm’s and Salix Pharmaceutical’s (SXLP) vapreotide, an octreotide analog for treating esophageal bleeding. Reviewers harshly questioned the drug’s safety and efficacy. The FDA Gastrointestinal Advisory Committee will review the drug on Tuesday. Shares of SXLP dropped on the news. [Reuters]

• Wellstat Therapeutics said its investigational drug vistonuridine showed good results in reducing potentially fatal side effects associated with 5-fluorouracil (5-FU); data will be presented at ASCO. [Company Website]

• Sanofi has launched Sanofi-aventis TV. It’s not as good as break.com, but it’s “OK.” [Pharmalive]

• The unluck of the Irish: AGI Therapeutics’ drug for irritable bowel syndrome, Rezular, failed a late stage trial sending company shares down 21 pence (53%) to 18.5 pence. What does a pence look like anyway? [WSJ]

• Gilead Sciences is suing Teva Pharmaceutical over emtricitabine for the second time. Teva is such a pain in the ass. [Pharmalive]

• GSK does it again! Gets swine flu vaccine stockpile orders from Britain, France, Belgium and Finland. [Reuters]

• Diagnostics-maker is in The Graveyard. [Xconomy]

• Northfield Laboratories: The Graveyard welcomes thee. [Yahoo!Finance]

• Finally, Pfizer says Lyrica, its drug for pain and seizures, also helps women with hot flashes. Who woulda thunk it??!! [Bloomberg]

Image from 0sw

Related Posts